<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03056339</url>
  </required_header>
  <id_info>
    <org_study_id>2016-0641</org_study_id>
    <secondary_id>NCI-2018-01221</secondary_id>
    <nct_id>NCT03056339</nct_id>
  </id_info>
  <brief_title>Umbilical &amp; Cord Blood (CB) Derived CAR-Engineered NK Cells for B Lymphoid Malignancies</brief_title>
  <official_title>Dose Escalation Study Phase I/II of Umbilical Cord Blood-Derived CAR-Engineered NK Cells in Conjunction With Lymphodepleting Chemotherapy in Patients With Relapsed/Refractory B-Lymphoid Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      If you are reading and signing this form on behalf of a potential participant, please note:&#xD;
      Any time the words &quot;you,&quot; &quot;your,&quot; &quot;I,&quot; or &quot;me&quot; appear, it is meant to apply to the potential&#xD;
      participant.&#xD;
&#xD;
      The goal of this clinical research study is to learn if giving genetically changed immune&#xD;
      cells, called CAR-NK cells, after chemotherapy will improve the disease in stem cell&#xD;
      transplant patients with relapsed (has returned) and/or refractory (has not responded to&#xD;
      treatment) B-cell lymphoma or leukemia. Also, researchers want to find the highest tolerable&#xD;
      dose of CAR-NK cells to give to patients with relapsed or refractory B-cell lymphoma or&#xD;
      leukemia. The safety of this treatment will also be studied.&#xD;
&#xD;
      This is an investigational study. The making of and infusion of genetically changed NK cells&#xD;
      and the drug AP1903 (if you receive it, explained below) are not FDA approved or commercially&#xD;
      available for use in this type of disease. They are currently being used for research&#xD;
      purposes only. The chemotherapy drugs in this study (fludarabine, cyclophosphamide, and&#xD;
      mesna) are commercially available and FDA approved.&#xD;
&#xD;
      Up to 36 patients will take part in this study. All will be enrolled at MD Anderson.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objectives:&#xD;
&#xD;
      Primary objective:&#xD;
&#xD;
      To determine the safety and relative efficacy of Chimeric antigen receptors&#xD;
      (CAR).CD19-CD28-zeta-2A-iCasp9-IL15-transduced cord blood natural killer (CB-NK) cells in&#xD;
      patients with relapsed/refractory CD19+ B lymphoid malignancies.&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
        1. To assess the overall response rate (complete and partial response rates).&#xD;
&#xD;
        2. To quantify persistence of infused allogeneic donor CAR-transduced CB-derived NK cells&#xD;
           in the recipient.&#xD;
&#xD;
        3. To conduct comprehensive immune reconstitution studies.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 21, 2017</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Optimal NK Cell Dose Level of Chimeric Antigen Receptors (CAR).CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood Natural Killer (CB-NK) Cells in Patients with Relapsed/Refractory CD19+ B Lymphoid Malignancies</measure>
    <time_frame>45 days</time_frame>
    <description>Dose-finding done using the sequentially adaptive phase I-II EffTox trade-off-based design. Toxicity is defined as a grade 3 or 4 GVHD within 45 days of NK cell infusion.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Toxicity of Chimeric Antigen Receptors (CAR).CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood Natural Liller (CB-NK) Cells in Patients with Relapsed/Refractory CD19+ B Lymphoid Malignancies</measure>
    <time_frame>2 weeks after NK cell infusion</time_frame>
    <description>Toxicity defined as cytokine release storm (CRS) within 2 weeks of NK cell infusion requiring transfer to intensive care.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy of Chimeric Antigen Receptors (CAR).CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood Natural Killer (CB-NK) Cells in Patients with Relapsed/Refractory CD19+ B Lymphoid Malignancies</measure>
    <time_frame>30 days after NK cell infusion</time_frame>
    <description>Efficacy defined as the patient being alive and in remission at day 30 post NK cell infusion.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response of Chimeric Antigen Receptors (CAR).CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood Natural Killer (CB-NK) Cells in Patients with Relapsed/Refractory CD19+ B Lymphoid Malignancies</measure>
    <time_frame>100 days after NK cell infusion</time_frame>
    <description>Unadjusted distributions of the time-to-event outcomes estimated using the method of Kaplan and Meier and their relationship to prognostic covariates and NK cell dose level evaluated by Bayesian piecewise exponential survival regression.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>B-Lymphoid Malignancies</condition>
  <condition>Acute Lymphocytic Leukemia</condition>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <condition>Non-hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>Fludarabine + Cyclophosphamide + CAR-NK Cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>On Days -5, -4, and -3, participants receive Fludarabine and Cyclophosphamide. Participants also receive Mesna before and after the cyclophosphamide dose.&#xD;
On Day 0, participants receive genetically modified NK cells as a cell infusion.&#xD;
If participant has graft-versus-host disease (GvHD) or cytokine release syndrome after the NK cell infusion, they receive AP1903 by vein and possibly steroids by mouth or by vein.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>30 mg/m2 by vein on Days -5 to -3.</description>
    <arm_group_label>Fludarabine + Cyclophosphamide + CAR-NK Cells</arm_group_label>
    <other_name>Fludarabine phosphate</other_name>
    <other_name>Fludara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>300 mg/m2 by vein on Days -5 to -3.</description>
    <arm_group_label>Fludarabine + Cyclophosphamide + CAR-NK Cells</arm_group_label>
    <other_name>Cytoxan</other_name>
    <other_name>Neosar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mesna</intervention_name>
    <description>300 mg/m2 by vein on Days -5 to -3 before and after the cyclophosphamide dose.</description>
    <arm_group_label>Fludarabine + Cyclophosphamide + CAR-NK Cells</arm_group_label>
    <other_name>Mesnex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>iC9/CAR.19/IL15-Transduced CB-NK Cells</intervention_name>
    <description>Infusion of iC9/CAR.19/IL15-transduced CB-NK cells on Day 0 by vein.&#xD;
Starting dose: 10E5</description>
    <arm_group_label>Fludarabine + Cyclophosphamide + CAR-NK Cells</arm_group_label>
    <other_name>NK cells</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AP1903</intervention_name>
    <description>If participant has graft-versus-host disease (GvHD) or cytokine release syndrome after the NK cell infusion, they will receive AP1903 0.4 mg/kg administered as an intravenous infusion.</description>
    <arm_group_label>Fludarabine + Cyclophosphamide + CAR-NK Cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with history of CD 19 positive B-lymphoid malignancies (ALL, CLL, NHL) who&#xD;
             have received at least 2 lines of standard chemoimmunotherapy or targeted therapy and&#xD;
             have persistent disease.&#xD;
&#xD;
          2. Patients with ALL, CLL, NHL with relapsed disease following standard therapy or a stem&#xD;
             cell transplant.&#xD;
&#xD;
          3. Patients at least 3 weeks from last cytotoxic chemotherapy at the time of starting&#xD;
             lymphodepleting chemotherapy. Patients may continue tyrosine kinase inhibitors or&#xD;
             other targeted therapies until at least two weeks prior to administration of&#xD;
             lymphodepleting chemotherapy.&#xD;
&#xD;
          4. Karnofsky/Lansky Performance Scale &gt; 70.&#xD;
&#xD;
          5. Adequate organ function: a. Renal: Creatinine clearance (as estimated by Cockcroft&#xD;
             Gault) &gt;/= 60 cc/min. b. Hepatic: ALT/AST &lt;/= 2.5 x ULN or &lt;/= 5 x ULN if documented&#xD;
             liver metastases, Total bilirubin &lt;/= 1.5 mg/dL, except in subjects with Gilbert's&#xD;
             Syndrome in whom total bilirubin must be &lt;/= 3.0 mg/dL. c. Cardiac: Cardiac ejection&#xD;
             fraction &gt;/= 50%, no evidence of pericardial effusion as determined by an ECHO or&#xD;
             MUGA, and no clinically significant ECG findings. d. Pulmonary: No clinically&#xD;
             significant pleural effusion, baseline oxygen saturation &gt; 92% on room air.&#xD;
&#xD;
          6. Able to provide written informed consent.&#xD;
&#xD;
          7. 7-80 years of age.&#xD;
&#xD;
          8. All participants who are able to have children must practice effective birth control&#xD;
             while on study. Acceptable forms of birth control for female patients include:&#xD;
             hormonal birth control, intrauterine device, diaphragm with spermicide, condom with&#xD;
             spermicide, or abstinence, for the length of the study. If the participant is a female&#xD;
             and becomes pregnant or suspects pregnancy, she must immediately notify her doctor. If&#xD;
             the participant becomes pregnant during this study, she will be taken off this study.&#xD;
             Men who are able to have children must use effective birth control while on the study.&#xD;
             If the male participant fathers a child or suspects that he has fathered a child while&#xD;
             on the study, he must immediately notify his doctor.&#xD;
&#xD;
          9. Signed consent to long-term follow-up protocol PA17-0483.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Positive beta HCG in female of child-bearing potential defined as not postmenopausal&#xD;
             for 24 months or no previous surgical sterilization or lactating females.&#xD;
&#xD;
          2. Known positive serology for HIV.&#xD;
&#xD;
          3. Presence of Grade 3 or greater toxicity from the previous treatment.&#xD;
&#xD;
          4. Presence of fungal, bacterial, viral, or other infection requiring IV antimicrobials&#xD;
             for management. Note: Simple UTI and uncomplicated bacterial pharyngitis are permitted&#xD;
             if responding to active treatment.&#xD;
&#xD;
          5. Presence of active neurological disorder(s).&#xD;
&#xD;
          6. Concomitant use of other investigational agents.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Loretta Nastoupil, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Loretta Nastoupil, MD</last_name>
    <phone>(713) 792-2860</phone>
    <email>lnastoupil@mdanderson.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bethany Overman, RN,BSN,CPN</last_name>
    <phone>713-745-4567</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Research Operations</last_name>
      <email>lnastoupil@mdanderson.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>February 14, 2017</study_first_submitted>
  <study_first_submitted_qc>February 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 17, 2017</study_first_posted>
  <last_update_submitted>July 15, 2021</last_update_submitted>
  <last_update_submitted_qc>July 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>B-Lymphoid Malignancies</keyword>
  <keyword>Relapsed/Refractory</keyword>
  <keyword>Acute lymphocytic leukemia</keyword>
  <keyword>ALL</keyword>
  <keyword>Chronic lymphocytic leukemia</keyword>
  <keyword>CLL</keyword>
  <keyword>Non-Hodgkin lymphoma</keyword>
  <keyword>NHL</keyword>
  <keyword>(CAR).CD19-CD28-zeta-2A-iCasp9-IL15-transduced cord blood natural killer cells</keyword>
  <keyword>CB-NK cells</keyword>
  <keyword>Fludarabine</keyword>
  <keyword>Fludarabine phosphate</keyword>
  <keyword>Fludara</keyword>
  <keyword>Cyclophosphamide</keyword>
  <keyword>Cytoxan</keyword>
  <keyword>Neosar</keyword>
  <keyword>AP1903</keyword>
  <keyword>Mesna</keyword>
  <keyword>Mesnex</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vidarabine</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

